Summary Metastatic melanoma, compared with other cancers, appears to be unusual because of its low frequency of p53 mutations and prevalence of wild-type p53 protein in advanced malignancy. Here, we examined the effects of wild-type and mutated p53 (143 Val-Ala) on tumorigenic and metastatic potential of two human melanoma cell lines. The cell line UISO-MEL-4 contains wild-type p53 and is tumorigenic, whereas UISO-MEL-6 lacks p53 and produces lung and liver metastasis upon s.c. injection into athymic mice. Our study showed that UISO-MEL-4 stably transfected with wild-type p53 cDNA driven by cytomegalovirus promoter-enhancer sequences expressed high levels of p53 and p21 and formed s.c. tumours in vivo. Mutated p53 (143 Val-Ala) expression, on the other hand, inhibited tumour growth in 50% of cases and produced significantly slower growing non-metastatic tumours. Reduced tumour growth involved necrotic as well as apoptotic cell death. Inhibition of tumour growth was abrogated by the addition of Matrigel (15 mg ml-1). With UISO-MEL-6 cells, stably transfected with mutant p53, tumour growth was delayed and metastasis was inhibited. In soft agar colony formation assay, both wild-type and mutant p53 transfectants reduced anchorage-independent colony formation in vitro. These data suggest that mutated (143 Val-Ala) p53, which retains DNA binding and some of the transactivation functions of the wild-type p53 protein, suppresses tumorigenic and metastatic potentials of human melanoma cell lines in vivo.
Metastatic melanoma, compared with other cancers, appears to be unusual because of its low frequency of p53 mutations and prevalence of wild-type p53 protein in advanced malignancy (Volkenandt et al, 1991; Castresana, 1993; Greenblatt et al, 1994; Lu and Kerbel, 1994; Montano et al, 1994; Rauth et al, 1993a) . Several studies, including ours, have reported a much higher level of p53 (2-to 20-fold), mostly wild type, in metastatic melanoma compared with normal melanocytes (Rauth et al, 1993a; Jiang et al, 1995) . A high level of wild-type p53 has also been detected at the advanced stage of melanoma in Matrigel-assisted melanoma progression model in athymic mice (Jiang et al, 1995) . Here, we examined the effects of wild-type and mutated (143 Val-Ala) p53 on tumorigenic and metastatic potentials of two human melanoma cell lines. The cell line UISO-MEL-4 contains wild-type p53 and is tumorigenic, whereas UISO-MEL-6 lacks p53 and is metastatic upon s.c. injection into athymic mice (Rauth et al, 1993a (Rauth et al, , 1994 (Rauth et al, , 1997 . We report that UISO-MEL-4 melanoma cells, stably transfected with wild-type p53 expression vector, expressed high levels of p53 and p21 and produced s.c. tumours in vivo as the vectortransfected or parental cells. Mutated p53 (143 Val-Ala) transfectants expressing very high level of p53 protein, on the other hand, inhibited tumour growth in 50% of cases and produced nonmetastatic tumours in the rest. Inhibition of tumour growth involved necrotic as well as apoptotic cell death. Inhibition of tumour growth was abrogated by the addition of Matrigel. These data suggest that the protein encoded by the mutant p53 gene, which retains DNA binding and some of the transcriptional regulatory properties of wild-type p53 Friedlander et al, 1996) , suppresses tumorigenic and metastatic potentials of human melanoma cell lines in vivo.
MATERIALS AND METHODS Cells and media
The human melanoma cell lines UISO-MEL-4, UISO-MEL-6 are derived from biopsies obtained from patients with metastatic melanoma (Rauth et al, 1994) . Cells were maintained in MEM-H [minimum essential medium with Hanks' balanced salt solution (Gibco, Grand Island, NY, USA)] containing fetal calf serum (2%), L-glutamine (1%), non-essential amino acids and penicillinstreptomycin (0.2%).
Plasmids and transfection experiments
The human wild-type p53 expression plasmid pC53-SN3, mutant p53 plasmid pC53-SCX3 and the expression vector pCMVNeoBam without p53 cDNA, originally constructed by Bert Vogelstein (Baker et al, 1990) , were used in our studies. The p53 expression plasmids contain wild-type or mutant (143 Val-Ala) p53 cDNA sequences under the control of cytomegalovirus (CMV) promoter-enhancer sequences. To isolate cells stably transfected with p53 expression plasmids or the expression vector, UISO-MEL-4 cells were co-transfected with plasmids pC53-SN3 or pC53-SCX3 and PIRVGalNeo as described previously (Rauth et al, 1997) . Three days after transfection, the cells were subcultured in the presence of 1 mg ml G418 (Sigma Chemical). The selective media with G418 was replaced every 3 days, and colonies that appeared after 10-14 days were pooled and subcultured for further analysis. and 0.1% Nonidet p-40 as described previously (Rauth et al, 1997) . Cell extracts containing equal amounts of protein (150 gg) were separated on a SDS 12.5% polyacrylamide gel. Proteins were transferred electrophoretically to a nitrocellular membrane, and the p53 proteins in the blot were detected with a 1:200 dilution of p53 monoclonal antibody Ab-2 (pAbI801, Oncogene Science) and the enhanced chemiluminescence system (Amersham).
Western blot analysis
Reverse transcriptase polymerase chain reaction (RT-PCR) for p53 and p21
p53 and p21 mRNAs in the transfected cells were analysed using RT-PCR of total cellular RNA as described previously (Rauth et al, 1993a; 1997) . To avoid the plateau effect, PCR reaction conditions were optimized and run for 25 cycles. The sequences of the primers used to amplify p53 cDNA are spaced 1225 bp apart and yield full-length cDNA fragment. Primer 1: 5'-AGACTGCCTTC-CGGGTCACT-3'; primer 2: 5'-GGGAACAAAGAAGTGGA-GAAT-3' as described previously (Kichina et al, 1996) . The sequences of the primers used to amplify p21 cDNA were obtained from published sequences (Volkenandt et al, 1991 Assay for tumorigenicity and metastasis Melanoma cells were harvested from tissue culture and resuspended in Hanks' balanced salt solution. A total of 1-2 x 106 viable cells in a 0.2-ml volume were injected subcutaneously in either flank in sets of five mice for each cell line as described (Rauth et al, 1993a Suppression of melanoma progression by mutated (143 Val-Ala) p53 2217 A B Figure 3 Immunostaining of p53 protein in UISO-MEL-6 (A) and its mutant p53 transfectants (B). Cells were grown and analysed for p53 protein as described in Figure 2 Figure 2 Immunocytochemical staining of p53 protein in UISO-MEL-4 (A) stably transfected with wild-type (B) and mutated p53 (C). Cells grown on coverslips were analysed for p53 protein using the labelled streptavidin-biotin (LSAB) staining kit (Oncogene Science) and antibody p53 (Ab-6) (Oncogene Science) specific for human wild-type and mutant p53. MAb p3, a non-specific IgGK prepared from BALB/C mouse myeloma p3-X63-88, was used to monitor non-specific binding in the analysis stained with haematoxylin and eosin. Immunocytochemical analysis of the cells was performed using the streptavidin biotin (LSAB) technique, based on the indirect immunoperoxidase method as described previously (Rauth et al, 1993a ). The LSAB kit was purchased from Dako, CA, USA, and antibody p53 (Ab-6), specific for human wild-type and mutant p53 was purchased from Oncogene Science. MAb p3, a non-specific IgGk prepared from BALB/c mouse myeloma p3-X63-88 (Rauth et al, 1993b) , was used to monitor non-specific binding in the analysis. Briefly, cells grown on coverslips were treated with 3% hydrogen peroxide, to inhibit endogenous peroxidase activity, and then with blocking serum (non-immune goat serum). Cells were then incubated with primary antibody, p53 Ab-6, after removing the blocking serum. The link antibody (biotynylated anti-mouse and anti-rabbit immunoglobulin) was then overlaid, followed by PBS wash. Cells were next exposed to streptavidin conjugated to peroxidase, followed by hydrogen peroxide and AEC (3-amino-9-ethylcarbazole, Dako) 
Figure 5 Expression of p21 mRNA in UISO-MEL-4 human melanoma cells stably transfected with wild-type and mutant p53. p21 mRNA was analysed by reverse transcription and polymerase chain reaction (RT-PCR) using primers that give rise to 224-bp p21 cDNA fragment. P2-microglobulin mRNA, used as an internal control, was also analysed by RT-PCR using primers that yield a 120-bp product precipitation procedure, cells were transfected with wild-type or mutant (143 Val-Ala) p53 cDNA containing expression vector, as described previously (Rauth et al, 1997) . The (143 Val-Ala) p53 mutant has been shown to retain DNA binding and some of the transactivation function of wild-type p53 Friedlander et al, 1996) . As a control, the expression vector pCMVNeoBam without p53 insert was also transfected into the cells under the same conditions. Three days after transfection, the cells were subcultured in the presence of 1 mg ml-' G418. The colonies that appeared after 10-14 days were pooled and expanded so that numerous colonies could be assessed simultaneously. Consistent with the premise that overexpression of wild-type p53 results in a selective disadvantage compared with mutant p53, we observed a lower number of colonies with wild-type p53 compared with that obtained with mutated p53 in the case of MEL-4 cells. In the case of UISO-MEL-6, which is p53 negative, none of the wild-type p53 transfectants survived. The transfectants with wild-type p53 were designated as MEL-4 WP and had the mutants MEL-4 MP or MEL-6MP. The transfectants with expression vector were designated as MEL-4 NP or MEL-6NP The stably transfected cells were then analysed for p53 protein expression using Western blot hybridization with p53 monoclonal antibody Ab-2 (PAbi 801, Oncogene Science). As shown in Figure   IA , high levels of p53 proteins were detected in MEL-4 WP and MEL-4 MP compared with parental MEL-4 cells. The MEL-4 MP cells expressed a very high level of p53 protein, and this accumulation could be due to stabilization of the mutant p53 by complex formation with wild-type p53 or other proteins (Zambetti et al, 1993) . Figure lB shows a high level of p53 protein in MEL-6MP and no p53 in parental MEL-6 cell line. To examine whether the transfectants express p53 uniformly in level and localization, p53 expression was also analysed immunocytochemically using p53 monoclonal antibody Ab-6 (Oncogene Science). As shown in Figure 2 , a high level of uniform immunostaining, both nuclear and cytoplasmic, was detected in p53 transfectants of the MEL-4 cell line. Figure 3 shows high level of uniform immunostaining in MEL-6MP cells. To determine whether a high level of p53 expression is not due to accumulation of the protein but due to transcription from the transfected plasmids, we analysed total cellular RNA from the transfectants using RT-PCR. As shown in Figure 4 , MEL-4 WP or MP expressed a higher level of p53 transcript than parental MEL-4 cells. As an internal control for p53 expression, we analysed P,-m mRNA levels using RT-PCR. The P2-m gene is ubiquitously expressed (Morrelo et al, 1990) and is used to monitor the levels of cDNA in RT-PCR. The P2-m band appears to be similar in intensity for all cell types and therefore indicates equal RNA loading of all samples. Taken together, these results show that p53 was expressed from the transfected plasmids in human melanoma cells.
Expression of the p21 gene is directly induced by wild-type p53 and is an important mediator of p53-dependent tumour growth suppression (El Diery et al, 1994) . To determine whether p53 in the stable transfectants induced p21 gene expression, p21 mRNA expression was analysed using RT-PCR. As shown in Figure 5 , an increased level of p21 mRNA was detected in the wild-type p53 transfectants. P2-Microglobulin mRNA, analysed using RT-PCR, remained unchanged in both wild-type and mutant p53 transfectants. The levels of p21 protein in the stable transfectants were also analysed by immunocytochemical analysis using antibody WafI (Ab-1). A higher level of immunostaining was detected in p53 wild-type transfectants compared with parental MEL-4 (data not shown), indicating the presence of high levels of p21 protein.
These results show that wild-type p53 expressed from the transfected plasmid induced p21 expression in MEL-4 WP cells.
In vitro growth characteristics of p53 transfectants The anchorage-dependent growth rates of wild-type and mutant p53 transfectants were then examined in culture media containing British Journal of Cancer (1998) 5% fetal calf serum (FCS). As shown in Figure 6 , the wild-type p53 transfected cells had a slightly higher growth rate than did parental MEL-4 cells or the mutant p53 transfectants. The anchorage-independent colony formation potential of the transfectants was also examined by allowing them to grow in 0.367% soft agar in culture media as described in Materials and methods. As seen in Table 1 , both wild-type and mutant p53 transfectants of MEL-4 showed significant reductions in colonyforming efficiency compared with parental cells (four-to tenfold less). Colony formation efficiency of MEL-6 mutant p53 transfectants was also less than parental cells (fourfold less). These data provide evidence that stably transfected wild-type or mutant p53 in melanoma cells confers retardation of anchorage-independent growth in vitro.
Inhibition of tumour growth by mutant (143 Val-Ala) p53 and abrogation by Matrigel
We next asked if stable transfection of wild-type or mutant pS3 cDNA containing pCMVNeo vector into melanoma cells in vitro would prevent tumour growth and metastasis in vivo in nude mice.
To this end, stable transfectants (1 x 104) were injected subcutaneously in two groups of mice (five mice per group) and tumour growth was measured twice a week. The results are summarized in Table 2 . All animals injected with parental, wild-type p53 transfectants or vector-transfected cells formed tumours, whereas only five out of ten animals injected with mutant p53 transfectants of MEL-4 showed tumours. These mutant p53-derived tumours grew slowly and were significantly smaller than controls. We next tested whether the addition of Matrigel can stimulate growth of p53 mutant tumours. Matrigel is a reconstituted basement membrane extract and, when co-injected with tumour cells, permits rapid tumour growth in nude mice (Kobayashi et al, 1994) . Our study showed that the addition of Matrigel in a 15 mg ml-' concentration stimulated the tumorigenicity of the cells. The suppressive effect of mutated p53 was abrogated, and tumours grew as quickly as the parental cells. With MEL-6 mutant p53 transfectants, tumour appearance was delayed and no metastatic colonies were detected in lung or liver. The parental MEL-6 cells gave rise to metastatic colonies in 40% of cases, as described previously (Rauth et al, 1994) . These data suggest that mutated (143 Val-Ala) p53 in melanoma cells suppressed certain steps of the tumour progression and that this effect is overcome by Matrigel.
To examine that expressions of the transfected constructs were not lost in tumour cells during their exposure to the circulatory system, the s.c. tumours were examined using immunocytochemical analysis. As shown in Figure 7 , a high level of p53 protein is expressed in the primary tumours formed from MEL-4 WP (B) or MEL-4MP (C) compared with that from MEL-4 cells (A). A high level of p53 was also detected in MEL-6MP tumours ( Figure 8B ) compared with no p53 in MEL-6 tumours ( Figure 8A ).
We next asked whether there is any change in melanin content in p53-expressing tumours. Melanin synthesis is the characteristic of differentiated melanoma cells (Rauth et al, 1990; 1993a; 1997) . The parental MEL-4 and MEL-6 cells are poorly pigmented, and an increase in melanin content in the transfectants would indicate presence of differentiated cells. The s.c. tumour tissues were examined histologically and no significant change in melanin synthesis was observed. However, p53 mutant tumours demonstrated a large number of necrotic and apoptotic cells compared with those obtained from parental or wild-type p53 cells. This may A Figure 7 Expression of p53 in sections of primary tumours. UISO-MEL-4 (A), wild-type p53 transfectants (B) and mutant p53 transfectants (C). Tumours were stained immunocytochemically using the monoclonal antibodies p53 (Ab-6) as described in Figure 2 explain, in part, why the tumours were significantly smaller than those of parental or MEL-4 WP cells. Taken together, these studies showed that stably transfected mutant (143 Val-Ala) p53 inhibited melanoma growth and progression in vivo.
DISCUSSION
In the present study, we examined the effects of wild-type and mutant (143 Val-Ala) p53 on tumorigenic and metastatic potentials of melanoma cell lines. We used p53 expression vectors containing cytomegalovirus promoter-enhancer sequences and calcium phosphate-mediated gene transfer approaches. The data Figure 8 Expression of p53 in sections of primary tumours of UISO-MEL-6 (A) and mutant p53 transfectants (B) analysed immunocytochemically using the monoclonal antibodies p53 (Ab-6) as described in Figure 2 provide evidence that wild-type p53-transfected cells produced s.c. tumours as the controls, whereas mutated p53 inhibited tumour growth and progression in vivo.
The independent growth rate was consistently inhibited in the primary tumour formation in the pooled, stable transfectants expressing mutated p53 in two independent tumorigenicity assays. In 50% of the inoculated mice, complete inhibition of tumour growth was observed with MEL-4 cells expressing mutated p53.
In the other 50% of mice, tumours grew at a very slow rate. The tumour sizes were significantly smaller than tumours produced by parental MEL-4 cells. The reason why tumours fail to form after the injection of a relatively large number of tumour cells is unclear at present, but it may result from alterations in tumour cell-host interactions such as angiogenesis. The MEL-6MP-derived s.c. tumours, unlike parental MEL-6 tumours, did not produce any metastatic colonies. To produce metastasis, tumour cells must complete several sequential and selective steps that include invasion, survival in the circulation, arrest in the distant capillary bed, extravasion into the distant organ and proliferation (Poste and Fidler, 1979) . The mechanisms by which mutated p53 inhibited melanoma cells to progress through these sequential steps is unknown at present. We observed many apoptotic cells in tumours derived from mutant p53 compared with that in parental or wildtype p53 tumours. Our Matrigel experiments showed that coinjection of Matrigel permitted tumour growth from mutant p53 transfectants as rapidly as the parental cells. These data suggest that expression of mutated p53 may have inhibited certain steps of tumour progression of human melanoma cells. It is not surprising that mutated (143 Val-Ala) p53 inhibits melanoma growth in the nude mice model. The protein encoded by the p53 mutant (143 Val-Ala) can still bind to the p53 DNA consensus element (Funk et al, 1992) and can retain some of the transactivation properties of wild-type p53 Friedlander et al, 1996) . Although we have not tested other p53 mutants, we do not expect that other mutants would behave as the 143 Val-Ala mutated form of p53 in melanoma in vivo. Until now, the 143 Val-Ala p53 mutation has not been detected in melanoma tissues or cell lines. Further study with more cell lines may suggest the potential of this p53 mutant in clinical implications against melanoma.
Our data also indicated that p53 wild-type cells escaped suppression of tumour growth. The established role of p53 is to suppress growth in many cell types through p21 (El Deiry et al, 1994) . In our study, we found that the wild-type p53 transfectants reduced soft agar colony formation, but failed to suppress tumour growth in vivo. It was possible that the cell line we examined could have acquired point mutation in the wild-type p53 gene during stable transfection. We considered this unlikely as exogenous wild-type p53 was similar to endogenous wild-type p53 using several criteria; for example, it increased p21 expression and induced CAT gene expression from the p53-responsive p21 promoter sequences in our preliminary experiments (data not shown). Several studies (including ours) demonstrated that mutations in the p53 gene are rare in metastatic melanoma, and wild-type p53 is expressed at a high level (Volkenandt et al, 1991; Castresana, 1993; Greenblatt et al, 1994; Lu et al, 1994; Montano et al, 1994; Rauth et al, 1993a) . Only one study (Florence et al, 1995) demonstrated that an increased level of p53 protein does not indicate an increased degree of malignancy in melanoma, but rather suggests a more favourable disease progression. In that study, paraffin-embedded primary and metastatic tumours from patients were analysed. In our experience, analysis of paraffin-embedded tissues using immunocytochemistry is very sensitive to the procedures used. It is still not clear whether variation in this study is due to difference in technical procedures used in immunocytochemical analysis. A recent study demonstrated that p53 expression increased during evolution from normal melanocytes to metastatic melanoma (Jiang et al, 1995) . The same study also reported temporal decrease in p53 protein levels with a corresponding increase in p21 levels during growth arrest and terminal differentiation in human melanoma cells treated with a combination of recombinant human fibroblasts (IFN-B) and the antileukaemic compound mezerein (MEZ). In the Matrigel-assisted melanoma progression model, a high level of p53 was also detected at an advanced stage of melanoma progression (Jiang et al, 1995) . Based on these studies, it is suggested that melanoma may represent an unusual malignancy in that it progresses to more advanced stages, even in the presence of elevated levels of wild-type p53. It is still not known whether a high level of wild-type p53 in metastatic melanoma is functionally active or not. Loss of normal p53 function could be reached in a variety of ways, e.g. formation of protein complexes with viral oncoproteins (e.g. the SV40 T antigen, adenovirus E1B, papillomavirus E6) and binding to cellular oncogene products (e.g. MDM2). The other possibility is that downstream genes of p53 are defective in metastatic melanoma. Currently, experiments are underway in our laboratory to test these possibilities.
